-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Today, BioIntervene, a San Diego-based biopharmaceutical company, announced the completion of a $30 million round of A-round financing to advance the development of its first candidate drug for the treatment of neuropathic pain, BIO-205, as well as the development of a portfolio of A3 adenosine receptors (A3AR) agitants that potentially treat inflammatory and neurodegenerative diseases.
BioIntervene expects BIO-205 to enter Phase 1 clinical trials in the second half of this year.
is a complex chronic disease, often referred to as nerve pain.
it occurs in peripheral nerves and certain brain regions damaged by trauma, disease or toxins.
common causes of neuropathic pain include surgical or post-traumatic nerve damage, herpes infection, cancer, chemotherapy drugs, and neurological disorders such as multiple sclerosis and metabolic diseases such as diabetes.
Slayback Pharma completed a $50 million Round B financing Today, Slayback Pharma, a New Jersey-based company, announced a $50 million Round B financing.
new funding will be used to expand and accelerate its extensive portfolio of generic and specialty pharmaceutical products.
Slayback focuses on the development of generics and specialty drugs.
so far, it has developed highly differentiated product pipelines.
the past two years, Slayback has filed several applications for simplified new drugs, many of which are potential first or second generics on the market.
january last year, the FDA approved a simplified application for a new drug for its hydroxygesterone Caproate injection to reduce the risk of premature birth in pregnant women.
is the first and only multi-dose bottled oxyglyceone Caproate injection approved through the FDA's simplified application for the new drug.
first round of financing of $40 million, Andy Diagnostics, Inc., which specializes in accurate tumor diagnosis, announced the completion of a $40 million financing.
The first round of financing after the spin-off of ThoughtDi Diagnostics will be mainly used for product development, including follow-up pipeline development of its world-first ANDiS closed automation next-generation sequencing technology (NGS) platform, pipeline development of early oncology diagnostic products based on the exosome platform, and expansion of third-party testing service product pipelines.
Think Di Diagnostics has two lines of business for third-party medical testing services and IVD (in-body diagnostics) products, with a range of product development pipelines, from early oncology diagnosis to tumor accompanying diagnostics to tumor dynamic monitoring.
has the world's first closed, fully automated NGS library preparation platform, the world's leading early oncology diagnostic marker (exosome) development platform.
chinese-first complementary diagnostic and accompanying diagnostic products based on these platforms are in clinical trials or are about to enter clinical trials.
: $30 Million Series A Financing, BioIntervene Announces, Retrieved Jan. 06, 2020, from a first round of $280 million financing after the spin-off, Retrieved Jan. 06, 2020, from slayback Pharma Announces investment of $50 million by The Everstone Group, Jan. 06, 2020, from.